152 related articles for article (PubMed ID: 11213967)
61. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
62. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.
Liu R; Varghese S; Rabkin SD
Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042
[TBL] [Abstract][Full Text] [Related]
63. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.
Connor J; Bannerji R; Saito S; Heston W; Fair W; Gilboa E
J Exp Med; 1993 Apr; 177(4):1127-34. PubMed ID: 8459207
[TBL] [Abstract][Full Text] [Related]
64. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals.
Coveney E; Clary B; Iacobucci M; Philip R; Lyerly K
Surgery; 1996 Aug; 120(2):265-72; discussion 272-3. PubMed ID: 8751592
[TBL] [Abstract][Full Text] [Related]
65. Independent cell types are involved in the induction of antimelanoma responses in C57BL/6 mice immunized with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim TS; Collins MK; Cohen EP
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):298-304. PubMed ID: 7904182
[TBL] [Abstract][Full Text] [Related]
66. Cytokine immunogene therapy.
Glick RP; Lichtor T; Cohen EP
Neurosurg Focus; 2000 Dec; 9(6):e2. PubMed ID: 16817685
[TBL] [Abstract][Full Text] [Related]
67. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
Clary BM; Coveney EC; Blazer DG; Philip R; Lyerly HK
Surgery; 1996 Aug; 120(2):174-81. PubMed ID: 8751580
[TBL] [Abstract][Full Text] [Related]
68. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells.
Divino CM; Chen SH; Yang W; Thung S; Brower ST; Woo SL
Breast Cancer Res Treat; 2000 Mar; 60(2):129-34. PubMed ID: 10845275
[TBL] [Abstract][Full Text] [Related]
69. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.
Hanes J; Sills A; Zhao Z; Suh KW; Tyler B; DiMeco F; Brat DJ; Choti MA; Leong KW; Pardoll DM; Brem H
Pharm Res; 2001 Jul; 18(7):899-906. PubMed ID: 11496947
[TBL] [Abstract][Full Text] [Related]
70. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma.
Ewend MG; Sampath P; Williams JA; Tyler BM; Brem H
Neurosurgery; 1998 Nov; 43(5):1185-93. PubMed ID: 9802862
[TBL] [Abstract][Full Text] [Related]
71. Induction of a CD3+/CD56+ lymphocyte population following gene therapy with transgenic IL-2 secreting fibroblasts in a child with peripheral neuroectodermal malignancy.
Engel BC; Laws HJ; Buttlies B; Kahn T; Göbel U; Burdach SE
Med Pediatr Oncol; 1998 Aug; 31(2):56-60. PubMed ID: 9680927
[TBL] [Abstract][Full Text] [Related]
72. Development and characterization of an interleukin-2-transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules.
Santin AD; Ioli GR; Hiserodt JC; Manetta A; Pecorelli S; DiSaia PJ; Granger GA
Am J Obstet Gynecol; 1996 Feb; 174(2):633-40. PubMed ID: 8623798
[TBL] [Abstract][Full Text] [Related]
73. Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors.
Rochlitz C; Jantscheff P; Bongartz G; Dietrich PY; Quiquerez AL; Schatz C; Mehtali M; Courtney M; Tartour E; Dorval T; Fridman WH; Herrmann R
Cancer Gene Ther; 1999; 6(3):271-81. PubMed ID: 10359213
[TBL] [Abstract][Full Text] [Related]
74. Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2.
Lesniak MS; Tyler BM; Pardoll DM; Brem H
J Neurooncol; 2003; 64(1-2):155-60. PubMed ID: 12952296
[TBL] [Abstract][Full Text] [Related]
75. Cancer therapy with DNA-based vaccines.
Cohen EP
Immunol Lett; 2000 Sep; 74(1):59-65. PubMed ID: 10996629
[TBL] [Abstract][Full Text] [Related]
76. Breast cancer gene therapy: transgenic immunotherapy.
Su N; Ojeifo JO; MacPherson A; Zwiebel JA
Breast Cancer Res Treat; 1994; 31(2-3):349-56. PubMed ID: 7881111
[TBL] [Abstract][Full Text] [Related]
77. Murine intracerebral interleukin-2 injection: pathological and immunological effects.
Yamasaki T; Kikuchi H; Paine JT; Yamashita J; Miyatake S; Iwasaki K; Kobayashi H; Namba Y; Hanaoka M
J Neurosurg; 1989 Nov; 71(5 Pt 1):732-40. PubMed ID: 2809728
[TBL] [Abstract][Full Text] [Related]
78. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70.
Douin-Echinard V; Robbins PD; Lotze MT; Favre G; Couderc B
Adv Exp Med Biol; 1998; 451():353-7. PubMed ID: 10026896
[No Abstract] [Full Text] [Related]
79. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer.
Elder EM; Lotze MT; Whiteside TL
Hum Gene Ther; 1996 Mar; 7(4):479-87. PubMed ID: 8800742
[TBL] [Abstract][Full Text] [Related]
80. Immunotherapeutic Approach to Breast Cancer: The Anti-Tumor Effect of Anti-IL-6 Monoclonal Antibodies in Malignant Mammary Tumor Implanted-Mice.
Abou-Shousha SA; Abdel-Mawla AAAS; Hassan SM
Egypt J Immunol; 2016 Jan; 23(1):57-66. PubMed ID: 28502153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
